sofosbuvir/velpatasvir / Generic mfg. 
Welcome,         Profile    Billing    Logout  
 20 Diseases   29 Trials   29 Trials   1253 News 


12345678910111213...1920»
  • ||||||||||  sofosbuvir/velpatasvir / Generic mfg.
    Trial primary completion date:  STORC: Sofosbuvir/Velpatasvir Treatment of Chronic Hepatitis C During Pregnancy (clinicaltrials.gov) -  Jan 13, 2025   
    P4,  N=100, Recruiting, 
    SOF/VEL + RBV may be considered for HCV retreatment in resource-limited settings. Trial primary completion date: Dec 2024 --> Jun 2025
  • ||||||||||  sofosbuvir/velpatasvir / Generic mfg.
    Journal:  Multivisceral Transplantation Utilizing Hepatitis C Virus-Viremic Donors for Hepatitis C Virus-Negative Recipient. (Pubmed Central) -  Jan 6, 2025   
    All recipients received posttransplant direct-acting antiviral therapy with sofosbuvir/velpatasvir (SOF/VEL [Epclusa])...One recipient died from post-transplant lymphoproliferative disorder (PTLD) and another developed end-stage renal disease (ESRD); both outcomes were ostensibly unrelated to HCV-donor status. The other two patients are progressing well without any evidence of allograft rejection.
  • ||||||||||  Valcyte (valganciclovir) / Roche, Mitsubishi Tanabe, Mavyret (glecaprevir/pibrentasvir) / AbbVie, Enanta Pharma
    Management of HCV-Infection in Pediatric Patients Undergoing HCT: A Single-Center Experience () -  Dec 7, 2024 - Abstract #ASH2024ASH_9409;    
    One patient received a reduced-intensity conditioning regimen consisting of fludarabine + cyclophosphamide...DAAs were started after discontinuation of immunosuppressive therapy, for 4/5 patients.The combination of drugs used was : glecaprevir + pibrentasvir (2 patients), sofosbuvir + velpatasvir and ledipasvir + sofosbuvir...Two patients developed CMV-reactivation and required pre-emptive therapy with valganciclovir...No data are currently available regarding the possibility of viral reactivation in patients receiving treatment before transplant. Larger studies are needed to assess the right timing of treatment based on clinical evaluations.
  • ||||||||||  sofosbuvir/velpatasvir / Generic mfg.
    Journal:  Current Self-reported Pain Before and After Cure of Hepatitis C Among Persons Who Actively Inject Drugs. (Pubmed Central) -  Oct 30, 2024   
    However, participants who failed treatment had significantly greater pain at the visit immediately following visit for SVR, which may relate to adverse psychological effects of treatment failure. Among those with baseline moderate or greater pain, pain scores declined post treatment, suggesting that treatment itself (irrespective of SVR) may be associated with improved pain.
  • ||||||||||  Tyvyt (sintilimab) / Eli Lilly, Lenvima (lenvatinib) / Eisai, Merck (MSD)
    Journal, Metastases:  Multidisciplinary approaches in the management of advanced hepatocellular carcinoma: Exploring future directions. (Pubmed Central) -  Oct 30, 2024   
    This case report demonstrated the efficacy of the combination therapy of transcatheter arterial chemoembolization, hepatic arterial infusion chemotherapy, epclusa, lenvatinib and sintilimab for a patient with advanced HCC, and the report can serve as a reference for clinical practice. We would also like to share some of our views.
  • ||||||||||  Sovaldi (sofosbuvir) / Gilead
    Trial completion date, Trial primary completion date:  Therapy for Hepatitis C Virus (HCV) in Primary Treatment Failure in Pakistan (clinicaltrials.gov) -  Oct 21, 2024   
    P=N/A,  N=318, Enrolling by invitation, 
    We would also like to share some of our views. Trial completion date: Dec 2024 --> Sep 2025 | Trial primary completion date: Sep 2024 --> Sep 2025
  • ||||||||||  voxilaprevir (GS-9857) / Gilead, Mavyret (glecaprevir/pibrentasvir) / AbbVie, Enanta Pharma
    HCV REINFECTION AMONG PEOPLE WHO USE DRUGS (PWUD) TREATED FOR HCV INFECTION: A LONG-TERM VIEW () -  Oct 15, 2024 - Abstract #AASLD2024AASLD_1266;    
    We demonstrate that a comprehensive, multidisciplinary approach to HCV therapy with maintenance in follow up after cure is associated with rates of reinfection below 1/100 py. Those who experienced reinfection appear to disengage from ongoing follow up more frequently prior to the reinfection being documented.
  • ||||||||||  sofosbuvir/velpatasvir / Generic mfg.
    A MULTICENTER REAL WORLD STUDY OF SOFOSBUVIR/VELPATASVIR FOR HIV/HCV COINFECTED PATIENTS () -  Oct 15, 2024 - Abstract #AASLD2024AASLD_1229;    
    Our data supports the offer of both treatments within the setting of this program for the treatment of HCV-infected PWUD, irrespective of the level of stability. sofosbuvir/velpatasvir(SOF/ VEL),either as monotherapy or in combination with ribavirin(RBV),exhibited robust virologic response and favorable safety outcomes in the treatment of HIV/HCV coinfected patients.
  • ||||||||||  ribavirin / Generic mfg., sofosbuvir/velpatasvir / Generic mfg.
    STRATEGIC APPROACHES FOR HCV MICRO-ELIMINATION IN HEMODIALYSIS POPULATION IN SHANGHAI () -  Oct 15, 2024 - Abstract #AASLD2024AASLD_1226;    
    Despite modest treatment rates, early screening, prompt diagnosis, and targeted education have been proven highly efficacious in China. Consistent dedication to these strategies is essential for achieving goal of HCV elimination.
  • ||||||||||  sofosbuvir/velpatasvir / Generic mfg., ledipasvir/sofosbuvir / Generic mfg.
    EVALUATION OF HEPATITIS C TREATMENT AND CARE MODEL IN PRIMARY HEALTHCARE CENTERS IN THE COUNTRY OF GEORGIA () -  Oct 15, 2024 - Abstract #AASLD2024AASLD_1213;    
    Our analysis shows the effectiveness of integrating a simplified HCV diagnosis and treatment model in PHCs. Countrywide expansion of this model is warranted to bridge the gaps in the hepatitis C care continuum and ensure high rates of treatment uptake, enabling Georgia to achieve hepatitis C elimination.
  • ||||||||||  sofosbuvir/velpatasvir / Generic mfg.
    SOFOSBUVIR/VELPATASVIR EFFECTIVENESS IN TREATING CHRONIC HEPATITIS C GENOTYPE 3: A REAL-WORLD STUDY IN XINJIANG, CHINA () -  Oct 15, 2024 - Abstract #AASLD2024AASLD_1207;    
    Background: To observe the effectiveness of the combination of sofosbuvir/velpatasvir (SOF/VEL) with or without ribavirin (RBV) in the real-world treatment of patients with chronic hepatitis C (CHC) genotype 3 (GT3). The virological response rate is high and the safety profile is good when treating patients with genotype 3 chronic hepatitis C and cirrhosis using SOF/VEL monotherapy or in combination with RBV.
  • ||||||||||  Mavyret (glecaprevir/pibrentasvir) / AbbVie, Enanta Pharma
    THREE FOR TWO OR ONE FOR THREE: EVALUATING HCV TREATMENT REGIMENS, COMPLIANCE, AND SUBPOPULATIONS () -  Oct 15, 2024 - Abstract #AASLD2024AASLD_1201;    
    Adherence remains a critical determinant of SVR, particularly among PWIDs and those with alcohol use disorder, highlighting the need for targeted interventions to enhance compliance in these groups. The findings advocate for tailored strategies addressing adherence barriers, thereby optimizing treatment outcomes in HCV management.
  • ||||||||||  sofosbuvir/velpatasvir / Generic mfg.
    Trial completion date, Trial primary completion date:  The Use of Hepatitis C Positive Kidneys in Hepatitis C Negative Kidney Transplant Recipients (clinicaltrials.gov) -  Aug 23, 2024   
    P2,  N=30, Active, not recruiting, 
    There was no difference in cytomegalovirus and BK viremia between groups. Trial completion date: May 2024 --> Mar 2026 | Trial primary completion date: May 2024 --> Mar 2026
  • ||||||||||  Trial completion date, Trial primary completion date:  KeY Treat: The Kentucky Viral Hepatitis Treatment Study (clinicaltrials.gov) -  Aug 22, 2024   
    P4,  N=374, Active, not recruiting, 
    Trial completion date: May 2024 --> Mar 2026 | Trial primary completion date: May 2024 --> Mar 2026 Trial completion date: Dec 2024 --> Apr 2025 | Trial primary completion date: Aug 2024 --> Apr 2025
  • ||||||||||  acetylcysteine solution / Generic mfg., sofosbuvir/velpatasvir / Generic mfg.
    A Case of Herbs and Dietary Supplements-Drug-Induced Liver Injury From Unripe Ackee Fruit! (Exhibit Hall E) -  Aug 20, 2024 - Abstract #ACG2024ACG_5346;    
    Figure: Figure 1A and 1B. High and Medium power micrograph which shows acidophil bodies that indicate active hepatitis, with "feathery" change of hepatocytes compatible with cholestasis, expanded portal tracts with chronic inflammation, and reactive ductules.
  • ||||||||||  Rituxan (rituximab) / Roche
    Acute Limb Ischemia Due to Cryoglobulinemia in HCV Cirrhosis (Exhibit Hall E) -  Aug 20, 2024 - Abstract #ACG2024ACG_3651;    
    Following the hospitalization, she was treated with Sofosbuvir/Velpatasvir resulting in sustained viral response and no recurrence of vasculitis...Treatment in the acute phase typically relies on induction therapy with the use of corticosteroids, however in severe cases rituximab has been shown to have some therapeutic benefit...It is important to consider cryoglobulinemic vasculitis in patients with chronic HCV infection and new findings of ischemia. Figure: Figure 1: Physical exam findings of left lower extremity hemorrhagic bullae and palpable purpura.
  • ||||||||||  Mavyret (glecaprevir/pibrentasvir) / AbbVie, Enanta Pharma
    Protocol for the Management of Hepatitis C Transferred Through Kidney Transplantation (Exhibit Hall E) -  Aug 20, 2024 - Abstract #ACG2024ACG_3381;    
    Notably, 8 of these 9 patients received DAA therapy for 12 weeks (6 sofosbuvir/velpatasvir and 2 glecaprevir/pibrentasvir), and all 8 patients had undetectable virus at 8 weeks of treatment with no side effects requiring early treatment termination. There were 11 HCV
  • ||||||||||  Mycobutin (rifabutin) / Pfizer, Lupin
    A Case of Mycobacterial Duodenitis (Exhibit Hall E) -  Aug 20, 2024 - Abstract #ACG2024ACG_2063;    
    Case Description/ We present a 54-year-old man with a history of AIDS, chronic adrenal insufficiency, disseminated histoplasmosis, resistant disseminated MAC, DLBCL, cryptococcal meningitis, HCV s/p Epclusa who had recent prolonged hospitalization for bacteremia and discharged home with plans for outpatient infusions...He is currently being treated with rifabutin, ethambutol due to known fluroquinolone resistance, and amikacin for resistant disseminated MAC...Treatment is usually a lifelong multidrug regimen with emphasis on adherence to anti-retroviral therapy. Figure: EGD picture of the 2nd portion of the duodenum showing abnormal mucosa with evidence of white patches that can seen in mycobacterial duodenitis.
  • ||||||||||  sofosbuvir/velpatasvir / Generic mfg.
    Neuro-Cryoglobulinemic Vasculitis After Hepatitis C Treatment and Sustained Viral Response (Exhibit Hall E) -  Aug 20, 2024 - Abstract #ACG2024ACG_1872;    
    Patient was treated with a course of Epclusa that started in April 2017 and finished in August 2017, with undetectable viral load during and after treatment, confirming eradication...This poster will discuss treatment, follow-up, and management of such a rare condition. Figure: Timeline of Case Presentation
  • ||||||||||  ALF Secondary to DILI With Concurrent Acute HCV (Exhibit Hall E) -  Aug 20, 2024 - Abstract #ACG2024ACG_1793;    
    She was treated for syphilis with 14 days of IV penicillin and for HSV with Valtrex, followed by daily prophylactic dosing...Prompt initiation of treatment and careful monitoring are crucial in improving the prognosis. Note: The table for this abstract can be viewed in the ePoster Gallery section of the ACG 2024 ePoster Site or in The American Journal of Gastroenterology's abstract supplement issue, both of which will be available starting October 27, 2024.
  • ||||||||||  sofosbuvir/velpatasvir / Generic mfg.
    New trial:  Hepatitis C Treatment in Idaho County Jails (clinicaltrials.gov) -  Jul 31, 2024   
    P=N/A,  N=100, Not yet recruiting, 
  • ||||||||||  ribavirin / Generic mfg., sofosbuvir/velpatasvir / Generic mfg., ledipasvir/sofosbuvir / Generic mfg.
    Journal:  Hepatitis C virus diversity and treatment outcomes in Benin: a (Pubmed Central) -  Jul 4, 2024   
    This study revealed a high SVR rate in Benin among individuals treated for HCV with sofosbuvir-velpatasvir, including those with highly diverse viral genotypes. Further studies of treatment effectiveness in genotypes 2d and 2b are indicated.
  • ||||||||||  sofosbuvir/velpatasvir / Generic mfg.
    Journal, HEOR, Cost-analysis:  A cost analysis of a simplified model for HCV screening and treatment at a tertiary hospital in Zimbabwe. (Pubmed Central) -  May 24, 2024   
    The total cost of screening and treatment was estimated to be US$2448 (SD=$290) per patient over a 12-week treatment duration using sofosbuvir/velpatasvir...The second largest cost driver was the cost of diagnosis, US$819, contributing 34.6% to the total cost of care. Screening and treatment of HCV-infected individuals using directly acting antivirals at a tertiary hospital in Zimbabwe may require substantial financial resources.